viewPharmaxis Ltd

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® .

The move addresses issues raised by the US Food and Drug Administration (FDA) in a complete response letter received in June 2019 and follows completion by Chiesi Group of a supplemental human factor study in the first quarter of 2020.

If Bronchitol is approved by the FDA, Pharmaxis will receive a US$10 million (A$15.5 million) milestone payment on the supply of Bronchitol for the US commercial launch and mid to high teen percentage royalties on in-market net sales.

Quick facts: Pharmaxis Ltd

Price: 0.082 AUD

Market: ASX
Market Cap: $32.57 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...


Pharmaxis enrols first patient in its bone marrow cancer trial

Pharmaxis Ltd's (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) Gary Phillips discusses with Proactive's Andrew Scott the news they've enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis. The trial aims to demonstrate that PXS‐5505, the...

6 days, 19 hours ago

2 min read